Abstract | Background: Methods: We assessed patients who underwent ASCT at the Heidelberg University Hospital between 2011 and 2020 for bleeding events, management strategies for ASA intake during thrombocytopenia, transfusion requirements, and the occurrence of CV events. Results: There were 57/1,113 patients who continued ASA until at least 1 day after ASCT; thus, a continuous platelet inhibition during thrombocytopenia was assumed. Most of the patients (41/57) continued ASA until they had a platelet count of 20-50/nl. This range reflects the kinetics of thrombocytopenia and nondaily measurements of platelets during ASCT. A tendency toward a higher risk for bleeding events in the ASA group was demonstrated (1.9% (control group) vs. 5.3% (ASA), p = 0.082). The risk factors for bleeding in multivariate analysis were the duration of thrombocytopenia < 50/nl, a history of gastrointestinal bleeding, and diarrhea. The factors predicting the duration of thrombocytopenia were age >60 years, a hematopoietic stem-cell transplantation comorbidity index ≥3, and an impaired bone marrow reserve at admission. CV events occurred in three patients; none of them took ASA or had an indication for APT. Conclusions:
|
Authors | Nina Rosa Neuendorff, Boryana Boshikova, Lutz Frankenstein, Marietta Kirchner, Christian Rohde, Hartmut Goldschmidt, Norbert Frey, Carsten Müller-Tidow, Karin Jordan, Sandra Sauer, Maike Janssen |
Journal | Frontiers in oncology
(Front Oncol)
Vol. 13
Pg. 1168120
( 2023)
ISSN: 2234-943X [Print] Switzerland |
PMID | 37182183
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Neuendorff, Boshikova, Frankenstein, Kirchner, Rohde, Goldschmidt, Frey, Müller-Tidow, Jordan, Sauer and Janssen. |